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The human immunodeficiency virus type 1 (HIV-1) protease (PR) makes five obligatory cleavages in the viral
Gag polyprotein precursor. The cleavage events release the virion structural proteins from the precursor and
allow the virion to undergo maturation to become infectious. The protease cleavage between the matrix protein
(MA) domain and the adjacent capsid protein (CA) domain releases CA from the membrane-anchored MA and
allows the N terminus of CA to refold into a structure that facilitates the formation of hexamer arrays that
represent the structural unit of the capsid shell. In this study, we analyzed the extent to which each of the HIV-1
Gag processing sites must be cleaved by substituting the P1-position amino acid at each processing site with
Ile. A mutation that blocks cleavage at the MA/CA processing site (Y132I) displayed a strong transdominant
effect when tested in a phenotypic mixing strategy, inhibiting virion infectivity with a 50% inhibitory concen-
tration of only 4% of the mutant relative to the wild type. This mutation is 10- to 20-fold more potent in
phenotypic mixing than an inactivating mutation in the viral protease, the target of many successful inhibitors,
and more potent than an inactivating mutation at any of the other Gag cleavage sites. The transdominant effect
is manifested as the assembly of an aberrant virion core. Virus containing 20% of the Y132I mutant and 80%
of the wild type (to assess the transdominant effect on infectivity) was blocked either before reverse transcrip-
tion (RT) or at an early RT step. The ability of a small amount of the MA/CA fusion protein to poison the
oligomeric assembly of infectious virus identifies an essential step in the complex process of virion formation
and maturation. The effect of a small-molecule inhibitor that is able to block MA/CA cleavage even partially
would be amplified by this transdominant negative effect on the highly orchestrated process of virion assembly.
Proteolytic cleavage of the human immunodeficiency virus
type 1 (HIV-1) polyproteins Gag and Gag-Pro-Pol by the viral
protease (PR) is an essential step in the maturation of the virus
particle to become infectious. Proteolysis occurs concomitantly
with the budding of the virus particle, and this processing
releases the following mature virion structural proteins from
the precursor proteins: matrix (MA), capsid (CA), spacer pep-
tide 1 (SP1), nucleocapsid (NC), spacer peptide 2 (SP2), p6,
and the viral enzymes (36). With the proteolysis of Gag, there
is a dramatic structural rearrangement in which the CA
proteins condense to form the cone-shaped capsid shell
surrounding the NC/RNA nucleoprotein complex (43). Dur-
ing maturation, the released N terminus of the CA protein
adopts a -hairpin structure by forming a salt bridge be-
tween Pro1 and Asp51 of CA, which appears to be impor-
tant for the assembly of conical capsid (21, 28, 38, 42). Since
proteolytic processing is essential for the formation of in-
fectious virus, PR has been the target of a very successful
group of inhibitors now in clinical use.
There are five protease cleavage sites in the Gag precursor
and an additional five sites in the Gag-Pro-Pol precursor. In
a previous analysis using a PR inhibitor, we found that only
moderate levels of inhibition of these cleavage events was
necessary to ablate virion infectivity (19). This observation
suggested that the processing/assembly pathway itself was a
more sensitive target for inhibition than PR and raised the
possibility that individual cleavage sites may not be equivalent
in the extent of cleavage needed for virion infectivity, with a
highly sensitive site representing a potential target for the
development of an antiviral. PA-457 (Bevirimat), identified in
a screen for inhibition of viral replication, inhibits the cleavage
event between CA and SP1 (23, 49), although it is not clear
how the drug blocks protease cleavage at this site. The drug is
incorporated into immature particles, suggesting that it inter-
acts with Gag to alter its ability to serve as a protease substrate
at the site (48). Thus, it is possible to envisage inhibitors that
could target specific processing sites.
Mutations that confer a dominant negative (also known as
transdominant) phenotype can be a powerful way to interfere
with the function of an oligomeric protein complex. Several
studies have described such mutations targeting HIV-1 pro-
teins such as Tat (17), Rev (5, 24), and Gag (15, 41), with a
dominant negative Rev mutant having been tested in a gene
therapy trial (1, 9, 35). In addition, an N-terminal mutation of
murine leukemia virus CA functions in a transdominant man-
ner (33). Most HIV-1 proteins function in a multimeric com-
plex, although the virion complex of several thousand Gag
proteins is by far the largest complex among the viral proteins
(7, 46). This suggests that mutant Gag proteins should have the
potential to display strong multiplicative effects on their inhi-
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bition of virion infectivity. In this study, we demonstrate a
strongly transdominant Gag mutant, Y132I. The inclusion of
only 5% of the Y132I mutant protein in a virion can inhibit
more than 80% of viral infectivity. Virus containing 20% of the
Y132I mutation and 80% of wild-type Y132I (W80/M20)
showed aberrant and eccentric core structures, a complete loss
of virion infectivity, and a large reduction in the ability to
synthesize viral DNA during the subsequent round of infec-
tion. These data demonstrate a potential to identify strongly
transdominant mutations in Gag that affect the assembly path-
way and validate this pathway as being a highly sensitive target
for the development of an antiviral.
MATERIALS AND METHODS
Constructs. The infectious molecular clone pNL-CH, derived from the
pNL4-3 clone of HIV-1, contains a silent T-to-C mutation at nucleotide 2600 to
introduce an RsrII restriction enzyme site near the 5 end of pol. Plasmid
pARKz1k1-5LTRgag, containing the fragment of the 5 long terminal repeat
(LTR) and the gag region of pNL-CH, was used as a template for site-directed
mutagenesis to introduce Y132I, L363I, M377I, N432I, F448I, D51A, P1F, or
P1L mutations. Point mutations were generated according to the Quickchange
method (Stratagene), and the mutations were confirmed by DNA sequence
analysis of the entire fragment subjected to mutagenesis. The DNA fragment
containing each mutation was prepared by restriction enzyme digestion with
BssHII and SpeI, and the resulting fragment was cloned into pNL-CH digested
with BssHII and SpeI. Each mutant clone in the pNL-CH backbone was con-
firmed by DNA sequence analysis.
Cell culture and DNA transfection. 293T cells and the TZM-BL cells (NIH
AIDS Research and Reference Reagent Program) were maintained in Dulbec-
co’s modified Eagle’s medium supplemented with 10% fetal calf serum in the
presence of penicillin and streptomycin at 37°C with 5% CO2. 293T cells are
derived from human embryonic kidney cells (13), and TZM-BL cells are HeLa
cells which stably express CXCR4, CCR5, and CD4 (44). Human astroglioma
U87 cells expressing human CD4 and CXCR4 (U87.CD4.CXCR4) (6) were
obtained from the NIH AIDS Research and Reference Reagent Program and
were maintained in Dulbecco’s modified Eagle’s medium with 15% fetal calf
serum in the presence of 1 g/ml puromycin, 300 g/ml G418, penicillin, and
streptomycin at 37°C with 5% CO2. To prepare a viral stock, 3.5  106 293T cells
were seeded onto a 10-cm plate 24 h before transfection. The 293T cells were
transfected with a total of 10 g of each mutant or the wild-type construct using
FuGENE 6 transfection reagent (Roche). For cotransfection, 0.5  106 293T
cells were seeded onto a six-well plate 24 h before transfection. 293T cells were
transfected with a total of 4 g of wild-type and mutant constructs using Fu-
GENE 6 transfection reagent (Roche). To prepare viruses grown in the presence
of the myristoylation inhibitor 2-hydroxymyristic acid, the culture supernatant of
293T cells transfected with wild-type and mutant constructs was changed 4 h after
transfection with medium containing the drug at concentrations between 0 and
30 M.
Infectivity assay. The culture supernatant containing virus particles was har-
vested 48 h after transfection and filtered through a 0.45-m-pore-size mem-
brane (Millipore) to remove cell debris. The culture supernatant was diluted 1:50
or 1:100 and used to infect 2  104 TZM-BL cells in a 96-well plate. The
TZM-BL indicator cells express the luciferase gene and the lacZ gene under the
control of the HIV-1 LTR. For the luciferase assay, infected TZM-BL cells were
lysed 48 h postinfection. Briefly, the culture medium was removed from each
well, and the cells were washed with phosphate-buffered saline. A 50-l aliquot
of 1 reporter lysis buffer (Promega) was added to the cells, and the cells were
kept at 80°C. After one freeze-thaw cycle, 30 l of cell lysate was transferred
into a 96-well assay plate (Costar), and luciferase activity was measured using a
luminometer (Promega).
Western analyses and EM. Viruses harvested 48 h posttransfection were
concentrated by ultracentrifugation at 24,000 rpm for 2 h at 4°C using an SW 41
Ti rotor (Beckman). Viral proteins were examined by Western analysis using
polyclonal rabbit anti-HIV-1 p24/CA antibody (NIH AIDS Research and Ref-
erence Reagent Program), polyclonal goat anti-HIV-1 p7/NC antibody (kind gift
from Robert Gorelick, SAIC-Frederick), or polyclonal rabbit anti-HIV-1 reverse
transcriptase (RT) antibody (NIH AIDS Research and Reference Reagent Pro-
gram). For electron microscopy (EM) analysis, 0.5  106 293T cells were seeded
onto a six-well plate 24 h before transfection. 293T cells were transfected with a
total of 4 g of each construct using FuGENE 6 transfection reagent (Roche).
The cells were washed with phosphate-buffered saline 48 h posttransfection,
pelleted by low-speed centrifugation, and fixed in 2% glutaraldehyde in cacody-
late buffer (0.1 M, pH 7.4). EM analyses were performed using thin-section
electron microscopy.
Quantitative analysis of viral RNA. Cell-free virions harvested from trans-
fected 293T cells were treated with RNase-free DNase (Promega) at 37°C for 1 h
to remove any residual plasmid DNA carried over from the transfection. Sindbis
virus was also treated with RNase-free DNase and used as an internal control for
real-time PCR. Viral RNA was extracted using the QIAamp viral RNA kit
(Qiagen). The amount of encapsidated genomic viral RNA was detected by
quantitative real-time RT-PCR using an ABI 7000 sequencer detector (Applied
Biosystems) and normalized by the amount of Sindbis virus RNA. The sequences
of the primers and probe to detect the HIV-1 gag region were previously de-
scribed (12). Sindbis virus RNA was detected using primers SINRT-F (5-GCC
GCACACGACAATTCAC-3) and SINRT-R (5-GTACCCTCGTACACGGA
CGAA-3) and a probe, SINRT-P (5-6-carboxyfluorescein-CCGCATCATCTG
AATTG-MGBNFQ-3, where MGBNFQ is minor groove binder nonfluorescent
quencher). Real-time PCR was performed using a TaqMan One-Step RT-PCR
master mix reagent kit (Applied Biosystems).
Quantitation of viral DNA synthesis. Filtered and DNase-treated virus super-
natant was used to infect U87.CD4.CXCR4 cells seeded 24 h before infection,
and total cellular DNA was isolated from the infected cells 24 h postinfection
using the QIAamp DNA blood minikit (Qiagen). The amount of recovered total
DNA in each sample was normalized by real-time PCR using a primer-and-probe
set detecting the human RNaseP gene (Applied Biosystems). The virus input
used for infection was determined by real-time RT-PCR using a primer-and-
probe set described above for virion RNA. Unless specified, a normalized
amount of total DNA from each sample was used as a template for quantitative
PCR to measure newly synthesized viral DNA. Primers used to detect an early
viral DNA product in the env gene were Henv7339F (5-TTTTAATTGTGGA
GGGGAATTTTTCTAC-3) and Henv7666R (5-ATATAATTCACTTCTCCA
ATTGTCCCTC-3). Primers to detect HIV-1 two-LTR circles (i.e., circular
DNA with two LTRs) were H9371F (5-CCGAGAGCTGCATCCGGAGTAC-3)
and H310R (5-GGATGCAGCTCTCGGGCCATG-3).
RESULTS
Isoleucine mutations at the P1 positions of Gag processing
sites. HIV-1 PR favors a large hydrophobic amino acid at the
P1 position (30), however, a -branched amino acid such as
isoleucine at the P1 position strongly inhibits protease cleavage
at that site (29). We created the following individual P1-posi-
tion mutants to test their relative potencies for inhibiting viral
infectivity in submolar amounts: Y132I, L363I, M377I, N432I,
and F448I (Fig. 1A).
Each of these cleavage site mutations except for the N432I
mutation ablated virion infectivity in virus particles produced
from 293T cells transfected with mutant viral DNA (Fig. 1B).
The N432I mutant showed infectivity at about 30% of wild-
type infectivity, and this is consistent with the phenotype de-
scribed previously (10). Western analysis of virus particles
(probed with an anti-CA antibody or an anti-NC antibody) are
shown in Fig. 1C and revealed the effect of the individual
mutations on Gag cleavage. Wild-type virus produced the ma-
ture CA protein (p24) with a small amount of a p40 processing
intermediate and unprocessed p55 Gag protein. The Y132I
mutation resulted in the production of p40 (MA/CA fusion
protein) showing a complete block at the processing site be-
tween MA and CA. The L363I mutation gave a product very
similar to p24, representing the CA/SP1 fusion protein (p25).
The band moving slightly faster than p25 is either p24 or a
p24-like product resulting from processing at minor sites in
SP1 (18, 45). The M377I mutation blocked processing at the
SP1/NC site and also showed a partial inhibition of cleavage at
the CA/SP1 site, generating a large amount of a CA/SP1/NC
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product (which also bound the anti-NC antibody) (data not
shown). The N432I mutation caused a partial processing defect
at the NC/SP2 site, generating an NC/SP2 product and the NC
protein. This analysis did not reveal processing defects with the
F448I mutation (at the SP2/p6 site), although we did not probe
the p6 protein. Some of the phenotypes described above are
equivalent to those observed previously for other mutations at
these sites (16, 45).
Transdominant negative activity of Y132I. In order to mod-
ulate the extent of cleavage at a specific site, we employed a
phenotypic mixing strategy by cotransfecting two DNAs, wild
type and mutant, to produce virus particles that contained a
mixture of proteins encoded by both genomes. Since assembly
takes place with the Gag precursor, the effect of a processing
defect would be apparent in the context of capsid maturation
in the virion, which is a large oligomeric structure requiring the
organization of several thousand CA subunits (7). To deter-
mine the potency of each processing site mutation in inhibiting
infectivity, we varied the ratios of the wild-type and mutant
genomes, keeping the total amount of DNA constant, and
measured the infectivity of the virus produced. For a control,
we included a genome that encodes a mutation at the active
site of the viral protease (D25A). As can be seen in Fig. 2A, the
PR mutant D25A-PR inhibited virion infectivity at a 50% level
(50% inhibitory concentration [IC50]) when approximately
50% of the viral DNA encoded the D25A mutation. Decreas-
ing amounts of protease activity resulted in the accumulation
of numerous processing intermediates (Fig. 2C, bottom), anal-
ogous to the titration of a protease inhibitor.
The five Gag cleavage site mutants (Y132I, L363I, M377I,
N432I, and F448I) behaved very differently in this phenotypic
mixing protocol (Fig. 2A). The Y132I mutant had a very strong
negative effect on wild-type infectivity, with only 5% of the
mutant DNA in the cotransfection inhibiting approximately
80% of the infectivity. In titrating down the amount of mutant
DNA, we found that as little as 3 to 4% of the mutant was able
to inhibit 50% of virion infectivity (IC50), and infectivity was
ablated with 20% mutant DNA (Fig. 2B). The M377I mutant
was also relatively potent, needing only 15% mutant to inhibit
50% of the infectivity, as was the F448I mutant, inhibiting 50%
of virion infectivity with 20% mutant. The L363I and N432I
mutants were the least potent, requiring approximately 70%
and 90% mutant, respectively, to inhibit 50% of the infectivity
(Fig. 2A). An examination of the Gag protein in the virus
particles produced from the cotransfection confirmed the ex-
pected processing patterns for mixtures of wild-type and mu-
tant Gag proteins (Fig. 2C and data not shown for N432I and
F448I). Based on the quantitative analysis of the viral RNA
(data not shown) and Western analysis (Fig. 2C), none of the
mutants appeared to block the production of virus particles,
suggesting that the loss of infectivity for each mutant was at
the level of particle infectivity. We also examined the extent
of processing of the Pol domain and found the appropriate pro-
cessing of the RT subunits for the Y132I mutant (Fig. 2D), indi-
cating that there were no global defects in processing. Thus, very
modest inhibition of processing at the MA/CA cleavage site re-
sulted in a dramatic loss in virion infectivity, a loss that was
disproportionate compared to the other four Gag processing site
mutations or compared to the inhibition of the viral protease.
We examined virion morphology using thin-section EM for
the Y132I mutant virions and for noninfectious virions that
contained 80% wild type and 20% of the Y132I mutant
[Y132I(W80/M20)] as a measure of transdominance. Since
even wild-type virions are polymorphic in structure, heteroge-
nous structures were expected. Immature ring structures and
mature cone-shaped cores are well described for wild-type
HIV-1, and examples are shown in Fig. 2F. The distinctive
structure that was apparent, especially in the mixed virions
containing 20% of the Y132I mutant, was an eccentric core
structure at the edge of the virion (Fig. 2F), suggesting residual
FIG. 1. Ile substitutions at the P1 position of Gag cleavage sites
affect Gag processing and impair viral infectivity. (A) Schematic dia-
gram showing protein domains of the HIV-1 Gag protein. Amino acid
sequences of the P1 position of the cleavage sites are shown in boldface
type. The Ile substitution mutants are shown with the cleavage site.
Arrows at the top indicate five different cleavage sites in Gag. (B) Rel-
ative infectivity of the P1 Ile mutant viruses. Culture supernatants of
293T cells were harvested 48 h after transfection and used to infect
TZM-BL reporter cells. The TZM-BL cells were lysed and used in a
luciferase assay 48 h after infection to assess the level of infection. The
measurements of infectivity from the luciferase assays were normalized
by the amount of viral genomic RNA in the infecting virus quantified
by real-time PCR analysis. Measurements from the infectious molec-
ular clone pNL-CH (wild type [WT]; derived from pNL4-3) were used
as the wild type and were considered to be 100%. The mean data with
standard errors from several experiments are shown. All the infection
data shown in this paper were obtained by following the same protocol
unless otherwise specified. (C) Western analysis of viral particles. Cul-
ture supernatants harvested 48 h after transfection were subjected to
ultracentrifugation to concentrate the viral particles. The pelleted viral
particles were analyzed by Western analysis using either anti-CA an-
tibody (top) or anti-NC antibody (bottom) as the primary antibody.
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FIG. 2. The Y132I mutation displays a strong transdominant effect on wild-type viral infectivity in a phenotypic mixing experiment. (A) Relative
potencies of Y132I, L363I, M377I, N432I, F448I, and D25A-PR mutants. Mutant and wild-type plasmid DNAs were cotransfected into 293T cells,
gradually increasing the percentage of mutant from 0% to 100%. The amounts of mutant used were 0%, 10%, 20%, 40%, 60%, 80%, 90%, and 100%
in each cotransfection experiment except for the Y132I mutant, where 5% mutant was added. Viral infectivity was considered to be 100% when 0%
mutant was used (i.e., 100% wild type), and all other viral infectivities obtained from different mutant fractions were compared to the 100% value for
the wild type. Unless specified, all the infectivity data are shown as means  standard errors. (B) Relative viral infectivity of the Y132I mutant at a low
range of mutant percentages, from 0% to 20%. (C) Western analysis of virion particles produced from transfection with wild-type and mutant DNAs.
Lane 1 represents a mock transfection where no DNA was used. The percentage of mutant used for each cotransfection is shown. Open arrowheads
indicate processed CA protein, and closed arrowheads in the Y132I, L363I, M377I, and D25A-PR mutants indicate the MA/CA fusion protein, CA/SP1
fusion protein, CA/SP1/NC fusion protein, and unprocessed Gag precursor, respectively. (D) Western analysis showing processed RT in viral particles
of the Y132I and Y132I(W80/M20) viruses probed with an anti-HIV-1 RT antibody. Closed arrowheads indicate the completely processed p66 and p51
subunits of RT. (E) Distribution of virion morphology. Total numbers of viruses counted were 96 for the wild type (WT), 147 for the Y132I mutant, and
72 for the Y132I(W80/M20) mutant. The fractions of mature, immature, eccentric, and aberrant viruses are shown. (F) Morphology of Y132I viruses and
viruses from cotransfection with a ratio of 80% wild type and 20% Y132I [Y132I(W80/M20)] assessed by thin-section EM. Examples of wild-type viruses
are shown in the first row. The phenotype of each virion is labeled. The bars in each image represent 100 nm.
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tethering to the membrane of the viral core and a structure
similar to that seen for virions produced with a limiting amount
of a protease inhibitor (19, 26). In addition, some ring-shaped
core structures were also observed for Y132I(W80/M20) vi-
ruses (Fig. 2F). Consistent with previously reported findings
for a Y132S mutant (16), the Y132I mutant alone showed
enhanced thickening near the virion membrane, presumably
due to the membrane-linked MA/CA fusion protein, and a
separate small dark staining core containing NC and RNA, a
phenotype which we term aberrant and which is distinct from
the eccentric phenotype. The relative proportions of the dif-
ferent forms of virions seen are shown in Fig. 2E. About 67%
of the Y132I(W80/M20) viruses displayed an eccentric core,
which is significantly different from the frequency of these
cores in wild-type (23%) and Y132I (20%) strains (P 
0.0001).
Role of core tethering to membrane in the transdominant
phenotype. Since the MA domain of Gag is responsible for the
targeting of Gag to the membrane (36), one possible explana-
tion for the detrimental effect of the MA/CA fusion protein on
viral infectivity is that the MA-linked CA protein anchored to
the membrane may still participate in capsid core assembly,
resulting in the entire capsid remaining tethered to the viral
membrane envelope. We tested this possibility by introducing
a G2A mutation into Gag to block N-terminal myristoylation
in the background of the Y132I mutation so that the MA/CA
fusion protein generated from the Y132I mutant genome
would not be anchored in the membrane. However, when the
double mutant (G2A/Y132I) was tested in the phenotypic mix-
ing protocol, the two mutations frequently became unlinked
during the cotransfection protocol by host cell-mediated re-
combination with wild-type DNA (data not shown; 3), preclud-
ing the use of this experimental strategy.
In an attempt to address this potential mechanism, we also
used the myristoylation inhibitor 2-hydroxymyristic acid to
block the myristoylation of the Gag and Gag-Pro-Pol proteins.
It was previously shown that nearly complete inhibition of Gag
myristoylation is required to prevent virus budding (27) and
that a Gag protein that cannot be myristoylated can act as a
dominant negative inhibitor (20). When we tested the G2A
mutant in phenotypic mixing experiments, we also found that
more than 80% of G2A mutant Gag was needed to inhibit viral
infectivity to low levels (Fig. 3A). We used drug concentrations
lower than the IC50 (IC50 of 30 M) (data not shown) to permit
the undermyristoylation of Gag while retaining significant infec-
tivity. If the transdominant mechanism of the MA/CA fusion
protein on viral infectivity is due to the CA protein being indi-
rectly anchored to the membrane and affecting downstream steps,
the phenotypically mixed virus particles generated in the presence
of the myristoylation inhibitor should acquire some viral infectiv-
ity since the dose response to the Y132I mutant protein is much
greater than the dose response to the loss of myristoylation.
Y132I mutant ratios tested in this experiment were 10%
[Y132I(W90/M10)] and 5% [Y132I(W95/M5)]. As shown in Fig.
3B, however, viral infectivity was essentially unchanged over a
wide range of inhibitor concentrations. With this experiment
strategy, we could not show a role for membrane tethering as the
mechanism of the Y132I inhibition of infectivity.
Effect of a D51A mutation blocking a salt bridge between
Pro1 and Asp51 on virion infectivity. Another possibility for
the transdominant mechanism of Y132I may involve the rear-
rangement of the N terminus of CA after the cleavage of the
MA/CA processing site by PR. All orthoretroviruses encode a
proline at the N terminus of CA (30). This proline plays a key
structural role, as it anchors a salt bridge between its ring
nitrogen and carboxylate group of a conserved aspartic acid
(D51 in HIV-1 CA), creating a new loop with the N-terminal
protein sequence that folds into a -hairpin structure (21, 28,
38, 42). Preventing cleavage at the MA/CA site would seques-
ter the proline from the formation of this loop, inhibiting
proper core assembly. We attempted to mimic this effect with
three different mutations by replacing the proline with either
phenylalanine or leucine (P1F and P1L) or by replacing aspar-
tic acid with alanine (D51A). P1F and P1L should permit
cleavage by the protease (30) but preclude the use of a ring
nitrogen in the salt bridge. As shown in Fig. 4A, the two proline
substitution mutants were relatively weak in their abilities to
inhibit virion infectivity in the phenotypic mixing assay; how-
ever, the D51A mutation was more potent, with an IC50 of
approximately 20% mutant, although this is still less potent
than the Y132I mutation. As expected, none of these muta-
tions blocked either particle production or processing of the
Gag precursor (Fig. 4B). While the D51A mutation strongly
inhibits virion infectivity, it did not fully recapitulate the strong
transdominant effect of the Y132I mutation. Therefore, we
conclude that the Y132I mutation has a more dramatic effect
FIG. 3. Inhibition of myristoylation of the Gag protein does not
relieve viral infectivity of the viruses containing either 5% or 10% of
the Y132I mutant. (A) Relative potency of a mutant lacking myris-
toylation (G2A). (B) Relative infectivity of the virus containing either
5% or 10% of the Y132I mutant in the presence of the myristoylation
inhibitor 2-hydroxymyristic acid. 293T cells were transfected with wild-
type and mutant DNAs, and the drug was added into the medium 4 h
after transfection. Culture supernatants were harvested 48 h after
transfection, and infectivity data were obtained according to the pro-
tocol described in the legend of Fig. 2. Mean data are shown.
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on viral infectivity that may include but extends beyond dis-
ruption of this highly conserved salt bridge.
Effect of the Y132I mutation on viral DNA synthesis. The
Y132I mutation blocks infectivity without significantly inhibit-
ing particle production (Fig. 2C), suggesting that an early step
in the virus life cycle is blocked by the incorporation of the
mutant protein into virions. We examined the effect of this Gag
mutant on viral DNA synthesis by infecting cells with either
wild-type virus, the Y132I mutant virus, or the Y132I(W80/
M20) virus using equivalent amounts of virus (as measured by
the amount of viral genomic RNA). To quantify the amount of
an early viral DNA product and the 2-LTR circular DNA
found in the nucleus, cells infected with these viruses were
harvested at 24 h postinfection, and total DNA was isolated
and used in semiquantitative PCR assays. The DNA isolated
from the cells infected with wild-type virus was serially diluted
for comparison. No detectable viral DNA was synthesized after
infection with the Y132I mutant (Fig. 5) even though viral
RNA was present in the virion (data not shown) and RT was
present and fully processed (Fig. 2D). The Y132I(W80/M20)
phenotypically mixed virions were able to synthesize an early
viral DNA product at approximately 10% of the wild-type
level. We also detected circular viral DNA from the
Y132I(W80/M20) virus at approximately 5% of the wild-type
level (Fig. 5). Thus, the results indicate that the presence of the
Y132I mutant form of the Gag protein blocks detectable viral
DNA synthesis either prior to or shortly after initiation, al-
though the transdominant Y132I(W80/M20) virion allows
some DNA synthesis but only at a low level, which can account
for most of the transdominant phenotype. The small discor-
dance between DNA synthesis and infectivity seen here and in
the murine leukemia virus (MLV) system (33) with an analo-
gous mutation must reflect either the stability of the viral DNA
synthesized or the functioning of the preintegration complex.
DISCUSSION
In the present study, we demonstrate a potent transdomi-
nant mutation, Y132I, inhibiting wild-type infectivity with an
IC50 in the range of 3 to 4% mutant to wild type. This is at least
10-fold more potent than the D25A PR mutant. However,
since PR must function as a dimer, a 50:50 mix of wild-type and
mutant PR results in only 25% of PR with two wild-type sub-
units. Thus, the Y132I mutation is actually 20-fold more potent
than targeting protease activity. An analogous mutation within
the Gag protein of MLV, S2D, blocking cleavage between p12
and CA showed a similar dominant-negative effect on wild-
type infectivity, with 33% mutant reducing virion infectivity to
3% (33). The MA/CA processing site mutant in HIV-1 appears
to be even more potent than the analogous mutation in MLV
(p12/CA) since only 10% of the Y132I mutant can reduce
virion infectivity to 4%.
RevM10, a transdominant mutant of the HIV-1 Rev pro-
tein, is the most extensively studied transdominant protein
of HIV-1. The expression of RevM10 in human T-cell lines
inhibits HIV-1 replication in vitro (2, 4, 5, 25). However, rel-
atively high levels of RevM10, an excess of the RevM10 protein
over wild-type Rev levels, appear to be required for a signifi-
cant inhibition of HIV replication (31), with approximately
FIG. 4. Mutations blocking salt bridge formation do not show po-
tency equivalent to that of the Y132I mutant. (A) Relative potency of
CA D51A, P1L, and P1F mutations. Phenotypic mixing experiments
were performed according to the protocol described in the legend of
Fig. 2. (B) Western analysis of viral particles harvested from the su-
pernatant of 293T cells transfected with mutant and wild-type DNAs.
The percentage of the mutant used for each cotransfection is shown.
Open arrowheads indicate processed CA proteins.
FIG. 5. Viral DNA synthesis in U87.CD4.CXCR4 cells infected
with wild-type (WT) and Y132I and Y132I(W80/M20) mutant viruses.
A 293T cell culture supernatant harvested at 48 h after transfection
was used to infect U87.CD4.CXCR4 cells. Total DNA was isolated
from the infected cells harvested at 24 h postinfection. To detect early
viral DNA products, primers derived from the env gene were used. A
separate set of primers was used to detect HIV-1 2-LTR circles as
evidence of the synthesis of full-length viral DNA and import into the
nucleus. For comparison, the PCR amplification of the wild-type sam-
ple was done in a dilution (dil.) series. Mock is a DNA sample isolated
from cells infected with the culture supernatant from mock transfec-
tion (no DNA). In other experiments, we have shown that the PCR
signal generated using this protocol is abolished if a viral DNA syn-
thesis inhibitor is included at the time of infection. In this experiment,
the lack of signal from the infection with the Y132I virus is consistent
with a lack of transfected plasmid DNA being carried over to the
infection.
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50% RevM10 mutant being needed to inhibit 50% of relative
p24 Gag expression (24). Although HIV-1 proteins function as
dimers (PR and RT), trimers (the surface and transmembrane
subunits of the Env protein), tetramers (integrase), or higher
oligomers (Rev), it seems unlikely that any mutation targeted
outside of the multimeric interactions of Gag assembly could
have an equivalently strong transdominant effect, suggesting
that on a quantitative basis, the Gag assembly pathway is likely
to be the most sensitive protein target in the virus life cycle. A
transdominant (dominant negative) effect has also been re-
ported for mutants of the capsid protein of poliovirus, support-
ing the idea that viral assembly pathways in general may be
sensitive targets for inhibition (11).
An HIV-1 inhibitor currently in development provides a
proof of concept for an inhibitor of a specific processing site.
The maturation inhibitor PA-457 reduces cleavage at the CA/
SP1 site (equivalent to the L363I mutation) (23, 49). It was
previously shown that the compound is incorporated into im-
mature HIV-1 particles, and this incorporation is largely elim-
inated by mutations at the CA/SP1 junction that confer PA-457
resistance (47, 48), implying a direct interaction between PA-
457 and Gag. Given that the CA/SP1 cleavage site is relatively
insensitive to inhibition (Fig. 2A), it seems likely that more
potent inhibitors of this nature could be developed by targeting
more sensitive steps in the assembly pathway, such as targeting
cleavage of the MA/CA site.
Although the data presented in this paper did not reveal the
exact mechanism of action of the dominant mutation, the
Y132I mutation by itself retains the CA protein to the mem-
brane-bound MA protein (Fig. 2F). In the transdominant neg-
ative setting, the viral core of Y132I(W80/M20) virus is asym-
metrically tethered to the viral envelope (Fig. 2F). However,
we could not rescue infectivity with a myristoylation inhibitor
under conditions where the transdominant effect should have
been much more sensitive to a gain of infectivity than the effect
of the inhibitor on the loss of infectivity (27). Thus, we cannot
account for the transdominant effect by membrane tethering.
This is consistent with a major reduction in levels of viral
DNA synthesis (Fig. 5), suggesting deleterious changes in
the replication complex and not simply tethering of the
complex to the host membrane. An MLV mutant containing
an S2D Gag protein which blocks cleavage between p12 and
CA also showed reductions in the amounts of viral DNA
synthesized in infected cells (33), although the reductions were
not as great as the one which we observed with HIV-1 Y132I
Gag proteins. Mutations in HIV-1 CA affecting either core
structure or core stability can lead to viruses that are defective
in DNA synthesis (8, 14, 39). This suggests that the formation
of a proper core is a prerequisite for downstream events such
as disassembly and reverse transcription. Our EM images (Fig.
2F) clearly show that the mutant Y132I(W80/M20) virus con-
tains an abnormal and eccentric core structure. Thus, this is
likely sufficient to account for the reduction in viral DNA
synthesis of the mutant virus. However, it is not clear how a
small portion of the Y132I Gag proteins can poison the entire
capsid assembly process. As an example that different pro-
tease-dependent steps may have different sensitivities to inhi-
bition, a recent study demonstrated that viruses generated in
the presence of a protease inhibitor had only a slight decrease
in the overall thermodynamic stability of the viral RNA dimer,
although the particles had incorrect core structures (26).
Our attempts to mimic the effect of a lack of processing at
the MA/CA cleavage site by blocking the -hairpin formation
did not show the equivalent transdominant potency. The D51A
mutation disrupts the CA Pro1-Asp51 salt bridge, rendering
the virus noninfectious (Fig. 4) (42); however, this mutation
was not as potent as the Y132I mutant in its transdominant
effect (Fig. 4). Moreover, mutations of Pro1 were even less
potent than the D51A substitution. Even though residues Pro1
and Asp 51 are highly conserved among retroviral capsid pro-
teins, it is possible that these mutations alone do not fully block
the conformational change, especially in the context of a mix-
ture of wild-type Gag. In this regard, mutations of several
amino acids within the -hairpin have only modest effects on
assembly and infectivity (43). The major difference in these
mutations is that the Y132I mutation exerts its effect through
a covalent bond, whereas all of the other less potent mutations
exert their effects through noncovalent bonds. Due to this
difference, the Y132I mutation may represent a theoretical
limit on the potency of a transdominant mutation on Gag
assembly/maturation.
Knowledge of a potent transdominant mutation in Gag fits
in with several therapeutic paradigms. As noted above, the
development of PA-457 represents a proof of concept for the
inhibition of the cleavage of a specific processing site. Other
inhibitors that target the complex process of Gag assembly are
being developed, including a small molecule that binds to a
pocket in the N-terminal domain of CA (CAP-1) (22, 37) and
a helical peptide that binds to the C-terminal domain of CA
(CAI) (34, 40). Finally, the utility of a protein with transdomi-
nant activity has been explored in the context of a gene therapy
trial using the dominant negative mutant of Rev, RevM10 (1,
32). An important limitation in defining the MA/CA cleavage
site as a drug target is the fact that in solution, this region is
unstructured (38). However, the potential multiplicative effect
of targeting this site argues for further efforts to exploit this
highly vulnerable step in the virus life cycle.
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